Cantor Fitzgerald Weighs in on Cabaletta Bio FY2026 Earnings

Cabaletta Bio, Inc. (NASDAQ:CABA - Free Report) - Equities research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Cabaletta Bio in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst J. Schimmer expects that the company will post earnings of ($0.95) per share for the year. The consensus estimate for Cabaletta Bio's current full-year earnings is ($2.34) per share.

Cabaletta Bio (NASDAQ:CABA - Get Free Report) last released its quarterly earnings results on Wednesday, May 21st. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.04).

Several other analysts have also recently weighed in on CABA. Guggenheim boosted their price objective on Cabaletta Bio from $23.00 to $25.00 and gave the stock a "buy" rating in a report on Thursday, May 15th. HC Wainwright reissued a "buy" rating and set a $25.00 price objective on shares of Cabaletta Bio in a report on Wednesday. Morgan Stanley dropped their price objective on Cabaletta Bio from $30.00 to $22.00 and set an "overweight" rating for the company in a report on Tuesday, April 1st. UBS Group dropped their price objective on Cabaletta Bio from $10.00 to $7.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Finally, Citigroup dropped their price objective on Cabaletta Bio from $17.00 to $13.00 and set a "buy" rating for the company in a report on Friday, May 16th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $20.33.

Cabaletta Bio Stock Performance

NASDAQ:CABA traded up $0.19 on Wednesday, hitting $1.99. 4,559,781 shares of the stock were exchanged, compared to its average volume of 1,641,605. The stock has a market capitalization of $100.98 million, a price-to-earnings ratio of -0.93 and a beta of 2.81. Cabaletta Bio has a 52 week low of $0.99 and a 52 week high of $10.54. The company's 50-day moving average price is $1.55 and its 200 day moving average price is $2.02.

Hedge Funds Weigh In On Cabaletta Bio

Several institutional investors and hedge funds have recently modified their holdings of CABA. SG Americas Securities LLC grew its position in shares of Cabaletta Bio by 23.3% in the 4th quarter. SG Americas Securities LLC now owns 43,259 shares of the company's stock valued at $98,000 after purchasing an additional 8,161 shares during the period. HealthInvest Partners AB grew its position in shares of Cabaletta Bio by 46.8% in the 4th quarter. HealthInvest Partners AB now owns 247,454 shares of the company's stock valued at $554,000 after purchasing an additional 78,932 shares during the period. Miller Financial Services LLC acquired a new position in shares of Cabaletta Bio in the 4th quarter valued at approximately $33,000. Thrivent Financial for Lutherans acquired a new position in shares of Cabaletta Bio in the 4th quarter valued at approximately $216,000. Finally, Intech Investment Management LLC grew its position in shares of Cabaletta Bio by 42.2% in the 4th quarter. Intech Investment Management LLC now owns 20,203 shares of the company's stock valued at $46,000 after purchasing an additional 5,999 shares during the period.

Cabaletta Bio Company Profile

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.